請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/80763完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 楊銘欽(Ming-Chin Yang) | |
| dc.contributor.author | Kuang-Chieh Hsueh | en |
| dc.contributor.author | 薛光傑 | zh_TW |
| dc.date.accessioned | 2022-11-24T03:15:42Z | - |
| dc.date.available | 2021-11-03 | |
| dc.date.available | 2022-11-24T03:15:42Z | - |
| dc.date.copyright | 2021-11-03 | |
| dc.date.issued | 2021 | |
| dc.date.submitted | 2021-10-20 | |
| dc.identifier.citation | 1. WHO. Tobacco. 2021 [cited 2021; Available from: https://www.who.int/news-room/fact-sheets/detail/tobacco. 2. Jha, P., et al., 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med, 2013. 368(4): p. 341-50. 3. Warren, G.W., et al., The 2014 Surgeon General's report: 'The health consequences of smoking--50 years of progress': a paradigm shift in cancer care. Cancer, 2014. 120(13): p. 1914-6. 4. Pirie, K., et al., The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet, 2013. 381(9861): p. 133-41. 5. Wen, C.P., et al., Smoking attributable mortality for Taiwan and its projection to 2020 under different smoking scenarios. Tob Control, 2005. 14 Suppl 1: p. i76-80. 6. 楊銘欽、范靜媛, 2000年台灣地區35歲以上民眾可歸因於吸菸之醫療費用。. 2002, TAIWAN: 國家衛生研究院 p212-9. 7. Lin, S.J., Estimating the determinants of smoking behavior in Taiwan. Subst Use Misuse, 2010. 45(4): p. 482-95. 8. Sepehripour, A.H., et al., Is there benefit in smoking cessation prior to cardiac surgery? Interact Cardiovasc Thorac Surg, 2012. 15(4): p. 726-32. 9. Nilsson, S., J.M. Carstensen, and G. Pershagen, Mortality among male and female smokers in Sweden: a 33 year follow up. J Epidemiol Community Health, 2001. 55(11): p. 825-30. 10. Fiore, M.C., D.E. Jorenby, and T.B. Baker, Smoking cessation: principles and practice based upon the AHCPR Guideline, 1996. Agency for Health Care Policy and Research. Ann Behav Med, 1997. 19(3): p. 213-9. 11. The Agency for Health Care Policy and Research Smoking Cessation Clinical Practice Guideline. JAMA, 1996. 275(16): p. 1270-80. 12. Clinical Practice Guideline Treating Tobacco, U., L. Dependence Update Panel, and Staff, A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med, 2008. 35(2): p. 158-76. 13. Stapleton, J.A. and R. West, A direct method and ICER tables for the estimation of the cost-effectiveness of smoking cessation interventions in general populations: application to a new cytisine trial and other examples. Nicotine Tob Res, 2012. 14(4): p. 463-71. 14. Cromwell, J., et al., Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA, 1997. 278(21): p. 1759-66. 15. Croghan, I.T., et al., Cost-effectiveness of treating nicotine dependence: the Mayo Clinic experience. Mayo Clin Proc, 1997. 72(10): p. 917-24. 16. Robinson, R., Cost-utility analysis. BMJ, 1993. 307(6908): p. 859-62. 17. Mason, J., M. Drummond, and G. Torrance, Some guidelines on the use of cost effectiveness league tables. BMJ, 1993. 306(6877): p. 570-2. 18. Stead, L.F., A.J. Carroll, and T. Lancaster, Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev, 2017. 3: p. CD001007. 19. Stead, L.F., et al., Physician advice for smoking cessation. Cochrane Database Syst Rev, 2013(5): p. CD000165. 20. Rice, V.H., et al., Nursing interventions for smoking cessation. Cochrane Database Syst Rev, 2017. 12: p. CD001188. 21. Lancaster, T. and L.F. Stead, Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev, 2017. 3: p. CD001292. 22. Whittaker, R., et al., Mobile phone-based interventions for smoking cessation. Cochrane Database Syst Rev, 2016. 4: p. CD006611. 23. Hartmann-Boyce, J., et al., Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev, 2018. 5: p. CD000146. 24. Cahill, K., et al., Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev, 2016(5): p. CD006103. 25. Cahill, K., et al., Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev, 2013(5): p. CD009329. 26. Stead, L.F., et al., Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev, 2016. 3: p. CD008286. 27. Baker, T.B., et al., Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial. JAMA, 2016. 315(4): p. 371-9. 28. Anthenelli, R.M., et al., Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet, 2016. 387(10037): p. 2507-20. 29. Hsueh, K.C., P.L. Tang, and H. McRobbie, Effectiveness of Varenicline Versus Combination Nicotine Replacement Therapy for Smoking Cessation: One-Year Outcomes in a Smoking Cessation Clinic in Taiwan. Nicotine Tob Res, 2021. 23(7): p. 1094-1102. 30. Davies, N.M., et al., Varenicline versus nicotine replacement therapy for long-term smoking cessation: an observational study using the Clinical Practice Research Datalink. Health Technol Assess, 2020. 24(9): p. 1-46. 31. Kaduri, P., et al., Real-world effectiveness of varenicline versus nicotine replacement therapy in patients with and without psychiatric disorders. J Addict Med, 2015. 9(3): p. 169-76. 32. An introduction to the methods of cost-effectiveness analysis. Drug Ther Bull, 2012. 50(7): p. 81-4. 33. Gupta, N., et al., Cost-Effectiveness Analysis and Decision Modelling: A Tutorial for Clinicians. J Clin Exp Hepatol, 2020. 10(2): p. 177-184. 34. Javitz, H.S., et al., Cost-effectiveness of varenicline and three different behavioral treatment formats for smoking cessation. Transl Behav Med, 2011. 1(1): p. 182-190. 35. Angevine, P.D. and S. Berven, Health economic studies: an introduction to cost-benefit, cost-effectiveness, and cost-utility analyses. Spine (Phila Pa 1976), 2014. 39(22 Suppl 1): p. S9-15. 36. Weinstein, M.C. and W.B. Stason, Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med, 1977. 296(13): p. 716-21. 37. Madae'en, S., N. Obeidat, and M. Adeinat, Using cost-effectiveness analysis to support policy change: varenicline and nicotine replacement therapy for smoking cessation in Jordan. J Pharm Policy Pract, 2020. 13: p. 65. 38. Chen, P.C., et al., A cost-benefit analysis of the outpatient smoking cessation services in Taiwan from a societal viewpoint. Nicotine Tob Res, 2012. 14(5): p. 522-30. 39. Berg, M.L., et al., Model-based economic evaluations in smoking cessation and their transferability to new contexts: a systematic review. Addiction, 2017. 112(6): p. 946-967. 40. Fiscella, K. and P. Franks, Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA, 1996. 275(16): p. 1247-51. 41. Feirman, S.P., et al., Medical costs and quality-adjusted life years associated with smoking: a systematic review. BMC Public Health, 2016. 16: p. 646. 42. Feenstra, T.L., et al., Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health, 2005. 8(3): p. 178-90. 43. Boyd, K.A. and A.H. Briggs, Cost-effectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow. Addiction, 2009. 104(2): p. 317-25. 44. Stapleton, J.A., A. Lowin, and M.A. Russell, Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness. Lancet, 1999. 354(9174): p. 210-5. 45. Bolin, K., B. Lindgren, and S. Willers, The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden. Chest, 2006. 129(3): p. 651-60. 46. Oster, G., et al., Cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking. JAMA, 1986. 256(10): p. 1315-8. 47. Stevermer, J., Cost-effectiveness of the nicotine patch. J Fam Pract, 1996. 43(2): p. 125-6. 48. Woolacott, N.F., et al., The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess, 2002. 6(16): p. 1-245. 49. Cornuz, J., et al., Cost-effectiveness analysis of the first-line therapies for nicotine dependence. Eur J Clin Pharmacol, 2003. 59(3): p. 201-6. 50. Ebbert, J.O., et al., Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res, 2009. 11(5): p. 572-6. 51. Mills, E.J., et al., Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann Med, 2012. 44(6): p. 588-97. 52. Brose, L.S., R. West, and J.A. Stapleton, Comparison of the effectiveness of varenicline and combination nicotine replacement therapy for smoking cessation in clinical practice. Mayo Clin Proc, 2013. 88(3): p. 226-33. 53. Tsai, S.T., et al., A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther, 2007. 29(6): p. 1027-39. 54. Jorenby, D.E., et al., Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA, 2006. 296(1): p. 56-63. 55. Gonzales, D., et al., Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA, 2006. 296(1): p. 47-55. 56. Bolin, K., et al., Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003. Respir Med, 2008. 102(5): p. 699-710. 57. Linden, K., et al., Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers. Curr Med Res Opin, 2010. 26(3): p. 549-60. 58. Mahmoudi, M., C.I. Coleman, and D.M. Sobieraj, Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation. Int J Clin Pract, 2012. 66(2): p. 171-82. 59. Park, D.J., Y.H. Kim, and E.J. Kim, Cost-Utility Analysis of Varenicline Versus Existing Smoking Cessation Strategies in Korea. Value Health, 2014. 17(7): p. A726. 60. Lutz, M.A., P. Lovato, and G. Cuesta, Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model. Hosp Pract (1995), 2012. 40(1): p. 24-34. 61. Athanasakis, K., et al., Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece. Clin Ther, 2012. 34(8): p. 1803-14. 62. Annemans, L., et al., Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis. Clin Drug Investig, 2009. 29(10): p. 655-65. 63. Hoogendoorn, M., P. Welsing, and M.P. Rutten-van Molken, Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin, 2008. 24(1): p. 51-61. 64. Hodgson, T.A., Cigarette smoking and lifetime medical expenditures. Milbank Q, 1992. 70(1): p. 81-125. 65. Ahmad, S., The cost-effectiveness of raising the legal smoking age in California. Med Decis Making, 2005. 25(3): p. 330-40. 66. Ahmad, S. and G.A. Franz, Raising taxes to reduce smoking prevalence in the US: a simulation of the anticipated health and economic impacts. Public Health, 2008. 122(1): p. 3-10. 67. Villanti, A.C., et al., Analysis of media campaign promoting smoking cessation suggests it was cost-effective in prompting quit attempts. Health Aff (Millwood), 2012. 31(12): p. 2708-16. 68. Javitz, H.S., et al., Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspective. Am J Manag Care, 2004. 10(3): p. 217-26. 69. Keeler, T.E., et al., The benefits of switching smoking cessation drugs to over-the-counter status. Health Econ, 2002. 11(5): p. 389-402. 70. Ruger, J.P., et al., Cost-effectiveness of motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women: a randomized controlled trial. Value Health, 2008. 11(2): p. 191-8. 71. Baker, C.L. and G. Pietri, A cost-effectiveness analysis of varenicline for smoking cessation using data from the EAGLES trial. Clinicoecon Outcomes Res, 2018. 10: p. 67-74. 72. Drouin, O., et al., Cost-effectiveness of a Smoking Cessation Intervention for Parents in Pediatric Primary Care. JAMA Netw Open, 2021. 4(4): p. e213927. 73. Bolin, K., et al., Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries. Eur J Public Health, 2009. 19(6): p. 650-4. 74. Annemans, L., et al., Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation. Prev Med Rep, 2015. 2: p. 189-95. 75. Howard, P., et al., Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics, 2008. 26(6): p. 497-511. 76. Orme, M.E., et al., Development of the health and economic consequences of smoking interactive model. Tob Control, 2001. 10(1): p. 55-61. 77. Zimovetz, E.A., et al., A review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities. J Eval Clin Pract, 2011. 17(2): p. 288-97. 78. Ebbert, J.O., Varenicline and combination nicotine replacement therapy are the most effective pharmacotherapies for treating tobacco use. Evid Based Med, 2013. 18(6): p. 212-3. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/80763 | - |
| dc.description.abstract | "前言:本研究之目的在對於兩種藥物(戒必適與尼古丁合併替代療法)探討其成本效益，並計算戒必適與尼古丁合併替代療法（尼古丁貼片+口香糖）之遞增成本效果比值(ICER)。 方法:本研究對象為南台灣某醫學中心戒菸門診個案，資料收集期間為2013年6月起至2019年3月，研究架構採取世代研究(cohort study)。共招募3,569名吸菸者，含戒必適 (N=2,870)或尼古丁合併替代療法(N=699)，經使用傾向評分匹配 (PSM)並採取 1:1 的匹配比率提高戒必適和尼古丁合併替代療法組之間變項的同質性。傾向評分匹配(PSM)使用後共有894個案被配對並進行成本效益分析。參與者接受了醫生的諮詢，並選擇戒必適 (N=447)或尼古丁合併替代療法(N=447)為戒菸藥物。使用戒必適和尼古丁合併替代療法者皆可以在90天內獲得8週的藥物供應補貼和最高8次就診。所有費用和一年的持續戒菸率將被記錄並統計。戒菸之效益則引用先前研究中數值(先前研究使用Markov Model和TreeAge軟體，以一年戒菸率計算男性和女性分別拯救的生命年 [LYs] 和質量調整生命年[QALYs])，並進一步計算 ICER( QALY和LY之遞增成本效果比值）。最後將QALY和LY以0~3%折現率搭配0~37%的復抽率進行敏感度分析。 結果:戒必適組男性戒菸者拯救每一LY 或QALY 的成本分別為9,912~ 41,089 NTD和7,387~25,739 NTD；戒必適組女性戒菸者拯救每一LY和QALY的成本分別為9,838~40,926 NTD和11,804~42,923 NTD。尼古丁合併替代療法組男性戒菸者拯救每一LY和QALY成本分別為14,072~56,368 NTD和 10,599~35,788 NTD；尼古丁合併替代療法組女性拯救每一LY 和QALY成本分別為26,014~147,731 NTD和28,251~127,844 NTD。戒必適組相較尼古丁合併替代療法組拯救每一LY可節省4,699~18,219 NTD，拯救每一QALY可節省3,487~11,332 NTD。所有敏感性分析結果均顯示戒必適組與尼古丁合併替代療法組比較之ICER占明顯優勢。亦即使用戒必適協助戒菸可以救回更多的LY或QALY並同時節省成本。 結論:本研究分析台灣某醫學中心的戒菸門診資料發現，與尼古丁合併替代療法比較，戒必適以較低成本拯救更多LY和 QALY，有佔優勢之遞增成本效果比值(ICER)。 " | zh_TW |
| dc.description.provenance | Made available in DSpace on 2022-11-24T03:15:42Z (GMT). No. of bitstreams: 1 U0001-1310202109504400.pdf: 1686187 bytes, checksum: 11de664d6c9789e0d313f38adcc7e3d2 (MD5) Previous issue date: 2021 | en |
| dc.description.tableofcontents | 口試委員會審定書 I 誌謝 II 中文摘要 III 英文摘要 V 目錄 VIII 表目錄 IX 附錄目錄 X Introduction 1 Methods 3 Study participants 3 Data Collection and Measures 6 Statistical Analysis 7 Cost 8 Effectiveness and Incremental Cost-Effectiveness Ratio 8 Sensitivity Analysis 9 Hypotheses 9 Results 10 Discussion 14 Conclusion 17 References 18 Appendix 1: Literature Reivew 32 Appendix 2: Baseline characteristics of study samples before PSM 48 | |
| dc.language.iso | en | |
| dc.subject | 遞增成本效果比值 | zh_TW |
| dc.subject | 生活品質調整後之生命年數 | zh_TW |
| dc.subject | 戒必適 | zh_TW |
| dc.subject | 生命年數 | zh_TW |
| dc.subject | 尼古丁合併療法 | zh_TW |
| dc.subject | 成本效果分析 | zh_TW |
| dc.subject | varenicline | en |
| dc.subject | combination nicotine replacement therapy | en |
| dc.subject | cost-effectiveness analysis | en |
| dc.subject | incremental cost-effectiveness ratios | en |
| dc.subject | quality-adjusted life year | en |
| dc.subject | Life Year | en |
| dc.title | 戒必適相對於合併尼古丁療法戒菸之成本效果分析：台灣某醫學中心之經驗 | zh_TW |
| dc.title | Cost-Effectiveness Analysis of Varenicline versus Combination Nicotine Replacement Therapy for Smoking Cessation: Experience from a Medical Center in Taiwan | en |
| dc.date.schoolyear | 109-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.author-orcid | 0000-0002-8289-6861 | |
| dc.contributor.oralexamcommittee | 李玉春(Hsin-Tsai Liu),林金定(Chih-Yang Tseng) | |
| dc.subject.keyword | 成本效果分析,戒必適,尼古丁合併療法,生命年數,生活品質調整後之生命年數,遞增成本效果比值, | zh_TW |
| dc.subject.keyword | cost-effectiveness analysis,varenicline,combination nicotine replacement therapy,Life Year,quality-adjusted life year,incremental cost-effectiveness ratios, | en |
| dc.relation.page | 49 | |
| dc.identifier.doi | 10.6342/NTU202103683 | |
| dc.rights.note | 同意授權(限校園內公開) | |
| dc.date.accepted | 2021-10-20 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 健康政策與管理研究所 | zh_TW |
| 顯示於系所單位： | 健康政策與管理研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-1310202109504400.pdf 授權僅限NTU校內IP使用（校園外請利用VPN校外連線服務） | 1.65 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。